NCT01410695View on ClinicalTrials.gov

Masitinib in Refractory Active Rheumatoid Arthritis

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

324

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG

masitinib 3 mg

DRUG

masitinib 6.0 mg

DRUG

methotrexate

DRUG

Placebo (methotrexate)

DRUG

Placebo (masitinib)

Trial Locations (1)

25301

ARTMEDI UPD s.r.o, Hostivice

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AB Science

INDUSTRY